http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Tue, 07 Apr 2026 09:01:51 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Corporate+News/enGene+changes+name+to+enGene+Therapeutics+as+it+nears+commercialization/26279244.html <p>enGene Holdings Inc. (NASDAQ: ENGN) announced it will change its corporate name to enGene Therapeutics Inc. effective April 8, 2026. The clinical-stage biotechnology company said the name change reflects its transition toward becoming a commercial organization ahead of potential approval of its lead drug candidate detalimogene voraplasmid in 2027.</p> <p>The company plans to submit a Biologics License Application for detalimogene in the second half of 2026. The drug candidate is currently being evaluated in the ongoing LEGEND Phase 2 trial for high-risk non-muscle invasive bladder cancer, including a pivotal cohort studying BCG-unresponsive patients with carcinoma in situ.</p> <p>"We're entering an important next http://www.streetinsider.com/Corporate+News/enGene+changes+name+to+enGene+Therapeutics+as+it+nears+commercialization/26279244.html Tue, 07 Apr 2026 09:01:51 -0400 A.06822034 A.50205019 ENGN ENGNW O.00706867 O.20026344 O.61395639 http://www.streetinsider.com/Corporate+News/enGene+changes+name+to+enGene+Therapeutics+as+it+nears+commercialization/26279244.html <p>enGene Holdings Inc. (NASDAQ: ENGN) announced it will change its corporate name to enGene Therapeutics Inc. effective April 8, 2026. The clinical-stage biotechnology company said the name change reflects its transition toward becoming a commercial organization ahead of potential approval of its lead drug candidate detalimogene voraplasmid in 2027.</p> <p>The company plans to submit a Biologics License Application for detalimogene in the second half of 2026. The drug candidate is currently being evaluated in the ongoing LEGEND Phase 2 trial for high-risk non-muscle invasive bladder cancer, including a pivotal cohort studying BCG-unresponsive patients with carcinoma in situ.</p> <p>"We're entering an important next http://www.streetinsider.com/Corporate+News/enGene+changes+name+to+enGene+Therapeutics+as+it+nears+commercialization/26279244.html Tue, 07 Apr 2026 09:01:51 -0400 A.06822034 A.50205019 ENGN ENGNW O.00706867 O.20026344 O.61395639 http://www.streetinsider.com/Corporate+News/enGene+changes+name+to+enGene+Therapeutics+as+it+nears+commercialization/26279244.html <p>enGene Holdings Inc. (NASDAQ: ENGN) announced it will change its corporate name to enGene Therapeutics Inc. effective April 8, 2026. The clinical-stage biotechnology company said the name change reflects its transition toward becoming a commercial organization ahead of potential approval of its lead drug candidate detalimogene voraplasmid in 2027.</p> <p>The company plans to submit a Biologics License Application for detalimogene in the second half of 2026. The drug candidate is currently being evaluated in the ongoing LEGEND Phase 2 trial for high-risk non-muscle invasive bladder cancer, including a pivotal cohort studying BCG-unresponsive patients with carcinoma in situ.</p> <p>"We're entering an important next http://www.streetinsider.com/Corporate+News/enGene+changes+name+to+enGene+Therapeutics+as+it+nears+commercialization/26279244.html Tue, 07 Apr 2026 09:01:51 -0400 A.06822034 A.50205019 ENGN ENGNW O.00706867 O.20026344 O.61395639 http://www.streetinsider.com/Corporate+News/enGene+changes+name+to+enGene+Therapeutics+as+it+nears+commercialization/26279244.html <p>enGene Holdings Inc. (NASDAQ: ENGN) announced it will change its corporate name to enGene Therapeutics Inc. effective April 8, 2026. The clinical-stage biotechnology company said the name change reflects its transition toward becoming a commercial organization ahead of potential approval of its lead drug candidate detalimogene voraplasmid in 2027.</p> <p>The company plans to submit a Biologics License Application for detalimogene in the second half of 2026. The drug candidate is currently being evaluated in the ongoing LEGEND Phase 2 trial for high-risk non-muscle invasive bladder cancer, including a pivotal cohort studying BCG-unresponsive patients with carcinoma in situ.</p> <p>"We're entering an important next http://www.streetinsider.com/Corporate+News/enGene+changes+name+to+enGene+Therapeutics+as+it+nears+commercialization/26279244.html Tue, 07 Apr 2026 09:01:51 -0400 A.06822034 A.50205019 ENGN ENGNW O.00706867 O.20026344 O.61395639 http://www.streetinsider.com/Corporate+News/enGene+changes+name+to+enGene+Therapeutics+as+it+nears+commercialization/26279244.html <p>enGene Holdings Inc. (NASDAQ: ENGN) announced it will change its corporate name to enGene Therapeutics Inc. effective April 8, 2026. The clinical-stage biotechnology company said the name change reflects its transition toward becoming a commercial organization ahead of potential approval of its lead drug candidate detalimogene voraplasmid in 2027.</p> <p>The company plans to submit a Biologics License Application for detalimogene in the second half of 2026. The drug candidate is currently being evaluated in the ongoing LEGEND Phase 2 trial for high-risk non-muscle invasive bladder cancer, including a pivotal cohort studying BCG-unresponsive patients with carcinoma in situ.</p> <p>"We're entering an important next http://www.streetinsider.com/Corporate+News/enGene+changes+name+to+enGene+Therapeutics+as+it+nears+commercialization/26279244.html Tue, 07 Apr 2026 09:01:51 -0400 A.06822034 A.50205019 ENGN ENGNW O.00706867 O.20026344 O.61395639 http://www.streetinsider.com/Corporate+News/enGene+changes+name+to+enGene+Therapeutics+as+it+nears+commercialization/26279244.html <p>enGene Holdings Inc. (NASDAQ: ENGN) announced it will change its corporate name to enGene Therapeutics Inc. effective April 8, 2026. The clinical-stage biotechnology company said the name change reflects its transition toward becoming a commercial organization ahead of potential approval of its lead drug candidate detalimogene voraplasmid in 2027.</p> <p>The company plans to submit a Biologics License Application for detalimogene in the second half of 2026. The drug candidate is currently being evaluated in the ongoing LEGEND Phase 2 trial for high-risk non-muscle invasive bladder cancer, including a pivotal cohort studying BCG-unresponsive patients with carcinoma in situ.</p> <p>"We're entering an important next http://www.streetinsider.com/Corporate+News/enGene+changes+name+to+enGene+Therapeutics+as+it+nears+commercialization/26279244.html Tue, 07 Apr 2026 09:01:51 -0400 A.06822034 A.50205019 ENGN ENGNW O.00706867 O.20026344 O.61395639 http://www.streetinsider.com/Corporate+News/enGene+changes+name+to+enGene+Therapeutics+as+it+nears+commercialization/26279244.html <p>enGene Holdings Inc. (NASDAQ: ENGN) announced it will change its corporate name to enGene Therapeutics Inc. effective April 8, 2026. The clinical-stage biotechnology company said the name change reflects its transition toward becoming a commercial organization ahead of potential approval of its lead drug candidate detalimogene voraplasmid in 2027.</p> <p>The company plans to submit a Biologics License Application for detalimogene in the second half of 2026. The drug candidate is currently being evaluated in the ongoing LEGEND Phase 2 trial for high-risk non-muscle invasive bladder cancer, including a pivotal cohort studying BCG-unresponsive patients with carcinoma in situ.</p> <p>"We're entering an important next http://www.streetinsider.com/Corporate+News/enGene+changes+name+to+enGene+Therapeutics+as+it+nears+commercialization/26279244.html Tue, 07 Apr 2026 09:01:51 -0400 A.06822034 A.50205019 ENGN ENGNW O.00706867 O.20026344 O.61395639 http://www.streetinsider.com/Press+Releases/enGene+Announces+Name+Change+to+enGene+Therapeutics+Inc./26279241.html <p class="bwalignc"> <i>Name change reflects transition towards potential commercial organization in 2027</i> </p><p class="bwalignc"> <i>Planned Biologics License Application (BLA) submission for detalimogene in 2H 2026</i> </p> <p> BOSTON &amp; MONTREAL--(BUSINESS WIRE)-- enGene Therapeutics Inc. (formerly, enGene Holdings Inc.) (Nasdaq: ENGN, “enGene” or the “Company”), a clinical-stage, non-viral genetic medicines company, is pleased to announce that it will change its corporate name to “enGene Therapeutics Inc.” effective April 8, 2026. The Company elected to change its corporate name to reflect the near-term transition to a commercial organization with the potential approval of detalimogene voraplasmid in 2027. enGene's ongoing LEGEND trial is investigating detalimogene across http://www.streetinsider.com/Press+Releases/enGene+Announces+Name+Change+to+enGene+Therapeutics+Inc./26279241.html Tue, 07 Apr 2026 08:00:00 -0400 A.06822034 A.50205019 ENGN ENGNW O.00706867 O.20026344 O.61395639 http://www.streetinsider.com/Press+Releases/enGene+Announces+Name+Change+to+enGene+Therapeutics+Inc./26279241.html <p class="bwalignc"> <i>Name change reflects transition towards potential commercial organization in 2027</i> </p><p class="bwalignc"> <i>Planned Biologics License Application (BLA) submission for detalimogene in 2H 2026</i> </p> <p> BOSTON &amp; MONTREAL--(BUSINESS WIRE)-- enGene Therapeutics Inc. (formerly, enGene Holdings Inc.) (Nasdaq: ENGN, “enGene” or the “Company”), a clinical-stage, non-viral genetic medicines company, is pleased to announce that it will change its corporate name to “enGene Therapeutics Inc.” effective April 8, 2026. The Company elected to change its corporate name to reflect the near-term transition to a commercial organization with the potential approval of detalimogene voraplasmid in 2027. enGene's ongoing LEGEND trial is investigating detalimogene across http://www.streetinsider.com/Press+Releases/enGene+Announces+Name+Change+to+enGene+Therapeutics+Inc./26279241.html Tue, 07 Apr 2026 08:00:00 -0400 A.06822034 A.50205019 ENGN ENGNW O.00706867 O.20026344 O.61395639 http://www.streetinsider.com/Press+Releases/enGene+Announces+Name+Change+to+enGene+Therapeutics+Inc./26279241.html <p class="bwalignc"> <i>Name change reflects transition towards potential commercial organization in 2027</i> </p><p class="bwalignc"> <i>Planned Biologics License Application (BLA) submission for detalimogene in 2H 2026</i> </p> <p> BOSTON &amp; MONTREAL--(BUSINESS WIRE)-- enGene Therapeutics Inc. (formerly, enGene Holdings Inc.) (Nasdaq: ENGN, “enGene” or the “Company”), a clinical-stage, non-viral genetic medicines company, is pleased to announce that it will change its corporate name to “enGene Therapeutics Inc.” effective April 8, 2026. The Company elected to change its corporate name to reflect the near-term transition to a commercial organization with the potential approval of detalimogene voraplasmid in 2027. enGene's ongoing LEGEND trial is investigating detalimogene across http://www.streetinsider.com/Press+Releases/enGene+Announces+Name+Change+to+enGene+Therapeutics+Inc./26279241.html Tue, 07 Apr 2026 08:00:00 -0400 A.06822034 A.50205019 ENGN ENGNW O.00706867 O.20026344 O.61395639 http://www.streetinsider.com/Press+Releases/enGene+Announces+Name+Change+to+enGene+Therapeutics+Inc./26279241.html <p class="bwalignc"> <i>Name change reflects transition towards potential commercial organization in 2027</i> </p><p class="bwalignc"> <i>Planned Biologics License Application (BLA) submission for detalimogene in 2H 2026</i> </p> <p> BOSTON &amp; MONTREAL--(BUSINESS WIRE)-- enGene Therapeutics Inc. (formerly, enGene Holdings Inc.) (Nasdaq: ENGN, “enGene” or the “Company”), a clinical-stage, non-viral genetic medicines company, is pleased to announce that it will change its corporate name to “enGene Therapeutics Inc.” effective April 8, 2026. The Company elected to change its corporate name to reflect the near-term transition to a commercial organization with the potential approval of detalimogene voraplasmid in 2027. enGene's ongoing LEGEND trial is investigating detalimogene across http://www.streetinsider.com/Press+Releases/enGene+Announces+Name+Change+to+enGene+Therapeutics+Inc./26279241.html Tue, 07 Apr 2026 08:00:00 -0400 A.06822034 A.50205019 ENGN ENGNW O.00706867 O.20026344 O.61395639 http://www.streetinsider.com/Press+Releases/enGene+Announces+Name+Change+to+enGene+Therapeutics+Inc./26279241.html <p class="bwalignc"> <i>Name change reflects transition towards potential commercial organization in 2027</i> </p><p class="bwalignc"> <i>Planned Biologics License Application (BLA) submission for detalimogene in 2H 2026</i> </p> <p> BOSTON &amp; MONTREAL--(BUSINESS WIRE)-- enGene Therapeutics Inc. (formerly, enGene Holdings Inc.) (Nasdaq: ENGN, “enGene” or the “Company”), a clinical-stage, non-viral genetic medicines company, is pleased to announce that it will change its corporate name to “enGene Therapeutics Inc.” effective April 8, 2026. The Company elected to change its corporate name to reflect the near-term transition to a commercial organization with the potential approval of detalimogene voraplasmid in 2027. enGene's ongoing LEGEND trial is investigating detalimogene across http://www.streetinsider.com/Press+Releases/enGene+Announces+Name+Change+to+enGene+Therapeutics+Inc./26279241.html Tue, 07 Apr 2026 08:00:00 -0400 A.06822034 A.50205019 ENGN ENGNW O.00706867 O.20026344 O.61395639 http://www.streetinsider.com/Press+Releases/enGene+Announces+Name+Change+to+enGene+Therapeutics+Inc./26279241.html <p class="bwalignc"> <i>Name change reflects transition towards potential commercial organization in 2027</i> </p><p class="bwalignc"> <i>Planned Biologics License Application (BLA) submission for detalimogene in 2H 2026</i> </p> <p> BOSTON &amp; MONTREAL--(BUSINESS WIRE)-- enGene Therapeutics Inc. (formerly, enGene Holdings Inc.) (Nasdaq: ENGN, “enGene” or the “Company”), a clinical-stage, non-viral genetic medicines company, is pleased to announce that it will change its corporate name to “enGene Therapeutics Inc.” effective April 8, 2026. The Company elected to change its corporate name to reflect the near-term transition to a commercial organization with the potential approval of detalimogene voraplasmid in 2027. enGene's ongoing LEGEND trial is investigating detalimogene across http://www.streetinsider.com/Press+Releases/enGene+Announces+Name+Change+to+enGene+Therapeutics+Inc./26279241.html Tue, 07 Apr 2026 08:00:00 -0400 A.06822034 A.50205019 ENGN ENGNW O.00706867 O.20026344 O.61395639 http://www.streetinsider.com/Press+Releases/enGene+Announces+Name+Change+to+enGene+Therapeutics+Inc./26279241.html <p class="bwalignc"> <i>Name change reflects transition towards potential commercial organization in 2027</i> </p><p class="bwalignc"> <i>Planned Biologics License Application (BLA) submission for detalimogene in 2H 2026</i> </p> <p> BOSTON &amp; MONTREAL--(BUSINESS WIRE)-- enGene Therapeutics Inc. (formerly, enGene Holdings Inc.) (Nasdaq: ENGN, “enGene” or the “Company”), a clinical-stage, non-viral genetic medicines company, is pleased to announce that it will change its corporate name to “enGene Therapeutics Inc.” effective April 8, 2026. The Company elected to change its corporate name to reflect the near-term transition to a commercial organization with the potential approval of detalimogene voraplasmid in 2027. enGene's ongoing LEGEND trial is investigating detalimogene across http://www.streetinsider.com/Press+Releases/enGene+Announces+Name+Change+to+enGene+Therapeutics+Inc./26279241.html Tue, 07 Apr 2026 08:00:00 -0400 A.06822034 A.50205019 ENGN ENGNW O.00706867 O.20026344 O.61395639 http://www.streetinsider.com/Business+Wire/enGene+Announces+Name+Change+to+enGene+Therapeutics+Inc./26279241.html <p class="bwalignc"> <i>Name change reflects transition towards potential commercial organization in 2027</i> </p><p class="bwalignc"> <i>Planned Biologics License Application (BLA) submission for detalimogene in 2H 2026</i> </p> <p> BOSTON &amp; MONTREAL--(BUSINESS WIRE)-- enGene Therapeutics Inc. (formerly, enGene Holdings Inc.) (Nasdaq: ENGN, “enGene” or the “Company”), a clinical-stage, non-viral genetic medicines company, is pleased to announce that it will change its corporate name to “enGene Therapeutics Inc.” effective April 8, 2026. The Company elected to change its corporate name to reflect the near-term transition to a commercial organization with the potential approval of detalimogene voraplasmid in 2027. enGene's ongoing LEGEND trial is investigating detalimogene across http://www.streetinsider.com/Business+Wire/enGene+Announces+Name+Change+to+enGene+Therapeutics+Inc./26279241.html Tue, 07 Apr 2026 08:00:00 -0400 A.06822034 A.50205019 ENGN ENGNW O.00706867 O.20026344 O.61395639 http://www.streetinsider.com/Business+Wire/enGene+Announces+Name+Change+to+enGene+Therapeutics+Inc./26279241.html <p class="bwalignc"> <i>Name change reflects transition towards potential commercial organization in 2027</i> </p><p class="bwalignc"> <i>Planned Biologics License Application (BLA) submission for detalimogene in 2H 2026</i> </p> <p> BOSTON &amp; MONTREAL--(BUSINESS WIRE)-- enGene Therapeutics Inc. (formerly, enGene Holdings Inc.) (Nasdaq: ENGN, “enGene” or the “Company”), a clinical-stage, non-viral genetic medicines company, is pleased to announce that it will change its corporate name to “enGene Therapeutics Inc.” effective April 8, 2026. The Company elected to change its corporate name to reflect the near-term transition to a commercial organization with the potential approval of detalimogene voraplasmid in 2027. enGene's ongoing LEGEND trial is investigating detalimogene across http://www.streetinsider.com/Business+Wire/enGene+Announces+Name+Change+to+enGene+Therapeutics+Inc./26279241.html Tue, 07 Apr 2026 08:00:00 -0400 A.06822034 A.50205019 ENGN ENGNW O.00706867 O.20026344 O.61395639 http://www.streetinsider.com/Business+Wire/enGene+Announces+Name+Change+to+enGene+Therapeutics+Inc./26279241.html <p class="bwalignc"> <i>Name change reflects transition towards potential commercial organization in 2027</i> </p><p class="bwalignc"> <i>Planned Biologics License Application (BLA) submission for detalimogene in 2H 2026</i> </p> <p> BOSTON &amp; MONTREAL--(BUSINESS WIRE)-- enGene Therapeutics Inc. (formerly, enGene Holdings Inc.) (Nasdaq: ENGN, “enGene” or the “Company”), a clinical-stage, non-viral genetic medicines company, is pleased to announce that it will change its corporate name to “enGene Therapeutics Inc.” effective April 8, 2026. The Company elected to change its corporate name to reflect the near-term transition to a commercial organization with the potential approval of detalimogene voraplasmid in 2027. enGene's ongoing LEGEND trial is investigating detalimogene across http://www.streetinsider.com/Business+Wire/enGene+Announces+Name+Change+to+enGene+Therapeutics+Inc./26279241.html Tue, 07 Apr 2026 08:00:00 -0400 A.06822034 A.50205019 ENGN ENGNW O.00706867 O.20026344 O.61395639 http://www.streetinsider.com/Business+Wire/enGene+Announces+Name+Change+to+enGene+Therapeutics+Inc./26279241.html <p class="bwalignc"> <i>Name change reflects transition towards potential commercial organization in 2027</i> </p><p class="bwalignc"> <i>Planned Biologics License Application (BLA) submission for detalimogene in 2H 2026</i> </p> <p> BOSTON &amp; MONTREAL--(BUSINESS WIRE)-- enGene Therapeutics Inc. (formerly, enGene Holdings Inc.) (Nasdaq: ENGN, “enGene” or the “Company”), a clinical-stage, non-viral genetic medicines company, is pleased to announce that it will change its corporate name to “enGene Therapeutics Inc.” effective April 8, 2026. The Company elected to change its corporate name to reflect the near-term transition to a commercial organization with the potential approval of detalimogene voraplasmid in 2027. enGene's ongoing LEGEND trial is investigating detalimogene across http://www.streetinsider.com/Business+Wire/enGene+Announces+Name+Change+to+enGene+Therapeutics+Inc./26279241.html Tue, 07 Apr 2026 08:00:00 -0400 A.06822034 A.50205019 ENGN ENGNW O.00706867 O.20026344 O.61395639 http://www.streetinsider.com/Business+Wire/enGene+Announces+Name+Change+to+enGene+Therapeutics+Inc./26279241.html <p class="bwalignc"> <i>Name change reflects transition towards potential commercial organization in 2027</i> </p><p class="bwalignc"> <i>Planned Biologics License Application (BLA) submission for detalimogene in 2H 2026</i> </p> <p> BOSTON &amp; MONTREAL--(BUSINESS WIRE)-- enGene Therapeutics Inc. (formerly, enGene Holdings Inc.) (Nasdaq: ENGN, “enGene” or the “Company”), a clinical-stage, non-viral genetic medicines company, is pleased to announce that it will change its corporate name to “enGene Therapeutics Inc.” effective April 8, 2026. The Company elected to change its corporate name to reflect the near-term transition to a commercial organization with the potential approval of detalimogene voraplasmid in 2027. enGene's ongoing LEGEND trial is investigating detalimogene across http://www.streetinsider.com/Business+Wire/enGene+Announces+Name+Change+to+enGene+Therapeutics+Inc./26279241.html Tue, 07 Apr 2026 08:00:00 -0400 A.06822034 A.50205019 ENGN ENGNW O.00706867 O.20026344 O.61395639 http://www.streetinsider.com/Business+Wire/enGene+Announces+Name+Change+to+enGene+Therapeutics+Inc./26279241.html <p class="bwalignc"> <i>Name change reflects transition towards potential commercial organization in 2027</i> </p><p class="bwalignc"> <i>Planned Biologics License Application (BLA) submission for detalimogene in 2H 2026</i> </p> <p> BOSTON &amp; MONTREAL--(BUSINESS WIRE)-- enGene Therapeutics Inc. (formerly, enGene Holdings Inc.) (Nasdaq: ENGN, “enGene” or the “Company”), a clinical-stage, non-viral genetic medicines company, is pleased to announce that it will change its corporate name to “enGene Therapeutics Inc.” effective April 8, 2026. The Company elected to change its corporate name to reflect the near-term transition to a commercial organization with the potential approval of detalimogene voraplasmid in 2027. enGene's ongoing LEGEND trial is investigating detalimogene across http://www.streetinsider.com/Business+Wire/enGene+Announces+Name+Change+to+enGene+Therapeutics+Inc./26279241.html Tue, 07 Apr 2026 08:00:00 -0400 A.06822034 A.50205019 ENGN ENGNW O.00706867 O.20026344 O.61395639 http://www.streetinsider.com/Business+Wire/enGene+Announces+Name+Change+to+enGene+Therapeutics+Inc./26279241.html <p class="bwalignc"> <i>Name change reflects transition towards potential commercial organization in 2027</i> </p><p class="bwalignc"> <i>Planned Biologics License Application (BLA) submission for detalimogene in 2H 2026</i> </p> <p> BOSTON &amp; MONTREAL--(BUSINESS WIRE)-- enGene Therapeutics Inc. (formerly, enGene Holdings Inc.) (Nasdaq: ENGN, “enGene” or the “Company”), a clinical-stage, non-viral genetic medicines company, is pleased to announce that it will change its corporate name to “enGene Therapeutics Inc.” effective April 8, 2026. The Company elected to change its corporate name to reflect the near-term transition to a commercial organization with the potential approval of detalimogene voraplasmid in 2027. enGene's ongoing LEGEND trial is investigating detalimogene across http://www.streetinsider.com/Business+Wire/enGene+Announces+Name+Change+to+enGene+Therapeutics+Inc./26279241.html Tue, 07 Apr 2026 08:00:00 -0400 A.06822034 A.50205019 ENGN ENGNW O.00706867 O.20026344 O.61395639